Article Details
Retrieved on: 2024-02-27 13:58:20
Tags for this article:
Click the tags to see associated articles and topics
Summary
Zealand Pharma, a biotech company in Denmark, reported its full year 2023 financial results, highlighting advancements in peptide-based therapeutics for obesity and rare diseases. Key tags such as "Dapiglutide" and "Survodutide" represent drugs in clinical trials with positive obesity-related outcomes. Partnerships with entities like Boehringer Ingelheim and the European Investment Bank have bolstered their financial position for ongoing research and development in the biotechnology field.
Article found on: www.biospace.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here